Congestive Heart Failure Market to Grow 8% Through 2036 as New Therapies Expand
Updated
Updated · PR Newswire · Jul 28
Congestive Heart Failure Market to Grow 8% Through 2036 as New Therapies Expand
1 articles · Updated · PR Newswire · Jul 28
Summary
$9 billion was the congestive heart failure market size across the seven major markets in 2025, with DelveInsight forecasting an 8% CAGR from 2026 to 2036.
21.1 million diagnosed prevalent heart-failure cases in the 7MM in 2025, including nearly 7.4 million in the United States, are expected to keep demand rising alongside aging populations and more cardiovascular disease.
New and emerging therapies are a key growth driver, with candidates including Cytokinetics' omecamtiv mecarbil, Novo Nordisk's ziltivekimab, BioCardia's CardiALLO and CardiAMP cell therapies, and Bayer's umiposgene parvec.
Recent treatment advances such as SGLT2 inhibitors, vericiguat, sacubitril/valsartan and ivabradine have broadened guideline-based care, while ongoing HFpEF and regenerative-therapy trials could further reshape the market.
With the CHF market soaring toward $19 billion, will revolutionary gene therapies or smart wearables ultimately dominate future cardiac care?
As heart failure treatments shift to advanced cell therapies and smart implants, could skyrocketing costs leave vulnerable aging populations behind?
Wearables are drastically reducing heart failure hospitalizations, but could digital fatigue and data privacy risks threaten this high-tech medical revolution?